Loss of AXIN1 regulates response to lenvatinib through a WNT/KDM5B/p15 signalling axis in hepatocellular carcinoma
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.17413 ↗At a glance
Journal article in British Journal of Pharmacology, 2025. Written by Chengfang Tang and 11 co-authors. Institution: Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China. Major MEDLINE topics: Axin Protein, Carcinoma, Hepatocellular, Liver Neoplasms, Protein Kinase Inhibitors. Cited 1 times so far (Crossref); 55 references. Funded by: National Natural Science Foundation of China, 'Xingliao Talents' Program of Liaoning Province, Natural Science Foundation of Shenyang.
Abstract (original language)
Background and Purpose As a highly heterogeneous cancer, hepatocellular carcinoma (HCC) shows different response rates to the multi‐kinase inhibitor lenvatinib. Thus, it is important to explore genetic biomarkers for precision lenvatinib therapy in HCC. Experimental Approach The effect and mechanism of AXIN1 mutation on HCC were revealed by cell proliferation assay, long‐term clone formation assay, sphere formation assay and small molecule inhibitor library screening. A new therapeutic strategy targeting HCC with AXIN1 mutation was evaluated in humanized models (patient‐derived xenograft [PDX] and patient‐derived organoid [PDO]). Key Results Based on The Cancer Genome Atlas (TCGA) data, we screened 6 most frequently lost tumour suppressor genes in HCC (TP53, ARID1A, AXIN1, CDKN2A, ARID2 and PTEN) and identified AXIN1 as the most crucial gene for lenvatinib sensitivity. Further study showed that AXIN1‐knockout HCC cells had a more malignant phenotype and lower sensitivity to lenvatinib in vitro and in vivo . Mechanistically, the WNT pathway and its target gene c‐Myc were activated when AXIN1 was missing, and the expression of tumour suppressor p15 was inhibited by transcription co‐repressors c‐Myc and Miz‐1, resulting in the exacerbation of the resistant phenotype. Screening of a library of epigenetic‐related enzyme inhibitors showed that a KDM5B inhibitor up‐regulated p15 expression, leading to increased sensitivity to lenvatinib in vitro and in vivo . Conclusion and Implications AXIN1‐deficient patients have a lower response to lenvatinib, which may be associated with suppression of p15 mediated by WNT pathway activation. KDM5B inhibitors can restore p15 levels, resulting in efficient killing of resistant cells in HCC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.
- Benxi Institute of Pharmaceutical Research, Shenyang Pharmaceutical University, Benxi, China.
- Clinical Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
- Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
ORCID profiles: Chunfu Wu
Funding
- National Natural Science Foundation of China
- 'Xingliao Talents' Program of Liaoning Province
- Natural Science Foundation of Shenyang
Cite
APA
Tang, C., Tang, C., Zhu, X., Wang, S., Yang, Y., Miao, Y., Zhao, X., Jia, L., Yang, J., Su, Y., Wang, L., & Wu, C. (2025). Loss of AXIN1 regulates response to lenvatinib through a WNT/KDM5B/p15 signalling axis in hepatocellular carcinoma. British Journal of Pharmacology. https://doi.org/10.1111/bph.17413
Vancouver
Tang C, Tang C, Zhu X, Wang S, Yang Y, Miao Y, et al. Loss of AXIN1 regulates response to lenvatinib through a WNT/KDM5B/p15 signalling axis in hepatocellular carcinoma. British Journal of Pharmacology. 2025. doi:10.1111/bph.17413
BibTeX
@article{Tang2025,
author = {Tang, Chengfang and Tang, Chu and Zhu, Xuanchi and Wang, Simeng and Yang, Yuan and Miao, Yu and Zhao, Xiaoyao and Jia, Lina and Yang, Jingyu and Su, Yang and Wang, Lihui and Wu, Chunfu},
title = {Loss of AXIN1 regulates response to lenvatinib through a WNT/KDM5B/p15 signalling axis in hepatocellular carcinoma},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.17413}
}
EUVIMED